FORTIFY: a phase 2b randomised trial evaluating the effect of orticumab on coronary inflammation (FAI-Score) in post myocardial infarction patients selects for patients with high residual FAI-Score
30 August 2026 (10:15 - 11:00)
Organised by: 
Abstract
Slides
About the speaker
University of Virginia, Charlottesville (United States of America)
5 More presentations in this session
Doctor S. Kuehne (Augsburg, DE)
Mr T. Artner (Vienna, AT)
Access the full session
The Event
ESC Congress 2026
30 August 2026
10:15 CET
You may be interested in
Congress Presentation
Congress Session
